Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Entrada Therapeutics, Inc. (NASDAQ:TRDA) has received an average consensus rating of "Moderate Buy" from six analysts, with price targets averaging around $25.67.
• The company reported a quarterly loss of ($1.04) EPS, missing expectations and generating revenue of only $1.98 million against an anticipated $8.17 million.
• Insider activity revealed significant stock sales, including a director selling 27,000 shares at $7.50 each, indicating potential concerns about the company's future financial performance.

Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) have received a consensus rating of "Moderate Buy" from the six analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $25.6667.

Several equities analysts recently commented on TRDA shares. Zacks Research raised shares of Entrada Therapeutics to a "hold" rating in a research report on Friday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Entrada Therapeutics in a research report on Saturday, September 27th. Finally, Wall Street Zen lowered shares of Entrada Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th.

Entrada Therapeutics Stock Performance

TRDA stock opened at $6.00 on Friday. The firm has a market cap of $228.24 million, a price-to-earnings ratio of -3.37 and a beta of -0.11. The firm has a 50-day simple moving average of $5.54 and a two-hundred day simple moving average of $7.13. Entrada Therapeutics has a one year low of $4.93 and a one year high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.18). The firm had revenue of $1.98 million for the quarter, compared to analysts' expectations of $8.17 million. Entrada Therapeutics had a negative net margin of 92.30% and a negative return on equity of 17.81%. As a group, equities analysts predict that Entrada Therapeutics will post 1.12 earnings per share for the current fiscal year.

Insider Activity at Entrada Therapeutics

In other Entrada Therapeutics news, Director Kush Parmar sold 27,000 shares of the firm's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $7.50, for a total transaction of $202,500.00. Following the completion of the transaction, the director directly owned 1,093,313 shares of the company's stock, valued at approximately $8,199,847.50. This trade represents a 2.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Ventures V. L.P. 5Am sold 20,065 shares of the firm's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total transaction of $150,487.50. Following the transaction, the insider directly owned 3,163,066 shares of the company's stock, valued at $23,722,995. This represents a 0.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,000 shares of company stock valued at $405,000 over the last ninety days. 8.11% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Entrada Therapeutics

Institutional investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio grew its stake in shares of Entrada Therapeutics by 6.2% during the 4th quarter. Public Employees Retirement System of Ohio now owns 17,259 shares of the company's stock worth $298,000 after purchasing an additional 1,000 shares during the period. Martingale Asset Management L P grew its stake in shares of Entrada Therapeutics by 4.0% during the 1st quarter. Martingale Asset Management L P now owns 40,163 shares of the company's stock worth $363,000 after purchasing an additional 1,540 shares during the period. Bank of America Corp DE grew its stake in shares of Entrada Therapeutics by 4.9% during the 4th quarter. Bank of America Corp DE now owns 35,721 shares of the company's stock worth $618,000 after purchasing an additional 1,660 shares during the period. Harbor Capital Advisors Inc. grew its stake in shares of Entrada Therapeutics by 14.0% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 15,277 shares of the company's stock worth $103,000 after purchasing an additional 1,874 shares during the period. Finally, Intech Investment Management LLC grew its stake in shares of Entrada Therapeutics by 15.7% during the 2nd quarter. Intech Investment Management LLC now owns 17,702 shares of the company's stock worth $119,000 after purchasing an additional 2,397 shares during the period. 86.39% of the stock is owned by hedge funds and other institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.